Abcam plc
ABCM US
ABCM USAbcam plc
United States Composite23.99
USD
- -
- -
Ex-Dividend Date
March 19
Held by Insiders
6.44%
Held by Institutions
88.22%
Short % of Float
2.43%
YTD Yield
37.32%
3Y Yield
11.89%
Company Description
- CEO
- Mr. Alan Thomas Hirzel BS, M.B.A., M.S.
- Full Time Employees
- 1,760
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Discovery Drive Cambridge United Kingdom CB2 0AX
- CIK
- 0001492074
- Website
- www.abcam.com
- Business
- Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. The company's principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, biochemicals, and cell signaling pathway tools. It serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. The company has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. It sells its products online. The company was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom. As of December 6, 2023, Abcam plc operates as a subsidiary of Danaher Corporation.